Sunshine Biopharma Inc. (SBFM) News
Filter SBFM News Items
SBFM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SBFM News From Around the Web
Below are the latest news stories about SUNSHINE BIOPHARMA INC that investors may wish to consider to help them evaluate SBFM as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! |
Sunshine Biopharma Moves Principal Office to New York CityNEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has moved its headquarters to New York City. The Company’s Head Office is now located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036 (Tel: 332-216-1147). The Company will maintain a satellite office at its previous hea |
Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key AcquisitionMONTREAL, QC / ACCESSWIRE / November 13, 2023 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today ... |
Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid ComplianceSunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has received a 180-day extension, until March 18, 2024, to achieve compliance with the Nasdaq $1.00 minimum bid price rule. |
It's Down 26% But Sunshine Biopharma, Inc. (NASDAQ:SBFM) Could Be Riskier Than It LooksTo the annoyance of some shareholders, Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) shares are down a considerable 26% in... |
When Will Sunshine Biopharma, Inc. (NASDAQ:SBFM) Breakeven?With the business potentially at an important milestone, we thought we'd take a closer look at Sunshine Biopharma... |
Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter. The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022. The increase was largely due to the |
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM). |
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-MarketMONTREAL, May 16, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expens |
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-MarketMONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Com |